Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Current Deferred Revenue: 2019

  • Pharming Group N.V's Current Deferred Revenue was N/A to -$1.6 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$1.6 million, marking a year-over-year change of. This contributed to the annual value of -$1.6 million for FY2019, which is N/A change from last year.
  • Pharming Group N.V's Current Deferred Revenue amounted to -$1.6 million in Q4 2019.
  • In the past 5 years, Pharming Group N.V's Current Deferred Revenue ranged from a high of -$1.6 million in Q4 2019 and a low of -$1.6 million during Q4 2019.
  • Moreover, its 1-year median value for Current Deferred Revenue was -$1.6 million (2019), whereas its average is -$1.6 million.